Trial Profile

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 21 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SGN-STNV (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Appendiceal cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; HER2 negative breast cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Pseudomyxoma peritonei; Solid tumours
Focus Adverse reactions
Sponsors Seagen

Most Recent Events

15 Mar 2024 Status changed from active, no longer recruiting to discontinued.
03 Oct 2023 Status changed from recruiting to active, no longer recruiting.
14 Jun 2023 Planned number of patients changed from 315 to 360.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com